Kaleido CEO Dan Menichella (AP Photo/Andrew Harnik)

Flag­ship-backed mi­cro­bio­me com­pa­ny Kalei­do Bio­sciences shuts down

Three months af­ter ini­ti­at­ing lay­offs, hit­ting pause on a planned COPD study and ter­mi­nat­ing an agree­ment with the COPD Foun­da­tion, Kalei­do Bio­sciences is now shut­ting down.

On Fri­day, the biotech’s board vot­ed to “im­me­di­ate­ly wind-down and cease all of the Com­pa­ny’s on­go­ing op­er­a­tions,” ac­cord­ing to an SEC fil­ing. CEO Daniel Menichel­la, CFO William Duke, and CSO Jo­han van Hyl­cka­ma Vlieg were let go im­me­di­ate­ly. Kalei­do’s stock price $KL­DO fell near­ly 76% to about 36 cents apiece.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.